Marc Ferrante

33.3k total citations · 9 hit papers
543 papers, 21.4k citations indexed

About

Marc Ferrante is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Marc Ferrante has authored 543 papers receiving a total of 21.4k indexed citations (citations by other indexed papers that have themselves been cited), including 409 papers in Genetics, 289 papers in Epidemiology and 176 papers in Surgery. Recurrent topics in Marc Ferrante's work include Inflammatory Bowel Disease (402 papers), Microscopic Colitis (250 papers) and Immunodeficiency and Autoimmune Disorders (76 papers). Marc Ferrante is often cited by papers focused on Inflammatory Bowel Disease (402 papers), Microscopic Colitis (250 papers) and Immunodeficiency and Autoimmune Disorders (76 papers). Marc Ferrante collaborates with scholars based in Belgium, United States and Canada. Marc Ferrante's co-authors include Séverine Vermeire, Gert Van Assche, Paul Rutgeerts, Maja Noman, Vera Ballet, Ingrid Arijs, Ann Gils, Kristel Van Steen, Hans Clevers and Stieneke van den Brink and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

Marc Ferrante

503 papers receiving 21.1k citations

Hit Papers

Long-term Expansion of Epithelial Organoids From Human Co... 2009 2026 2014 2020 2011 2013 2020 2016 2015 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Long-term Expansion of Epithelial Organoids From Human Colon, Adenoma, Adenocarcinoma, and Barrett's Epithelium
    2011 2.6k citations Marc Ferrante et al. Gastroenterology profile →
  2. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis
    2013 1.4k citations Marie Joossens, João Sabino et al. Gut profile →
  3. Ulcerative colitis
    2020 1.1k citations Britta Siegmund, Marc Ferrante et al. profile →
  4. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial
    2016 738 citations Julián Panés, Gert Van Assche et al. profile →
  5. Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
    2015 636 citations Niels Vande Casteele, Marc Ferrante et al. Gastroenterology profile →
  6. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease
    2012 628 citations Geert D’Haens, Marc Ferrante et al. Inflammatory Bowel Diseases profile →
  7. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs disease
    2009 533 citations Marc Ferrante, Maja Noman et al. Inflammatory Bowel Diseases profile →
  8. Development of organoids from mouse and human endometrium showing endometrial epithelium physiology and long-term expandability
    2017 304 citations Marc Ferrante et al. profile →
  9. Deep learning for liver tumor diagnosis part I: development of a convolutional neural network classifier for multi-phasic MRI
    2019 245 citations Marc Ferrante et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marc Ferrante Belgium 64 12.4k 8.9k 5.3k 4.7k 4.6k 543 21.4k
Julián Panés Spain 84 14.2k 1.1× 11.2k 1.3× 8.5k 1.6× 4.8k 1.0× 2.8k 0.6× 590 26.0k
Toshifumi Hibi∥ Japan 81 9.9k 0.8× 8.3k 0.9× 7.6k 1.4× 7.1k 1.5× 5.3k 1.2× 788 26.6k
María T. Abreu United States 76 10.1k 0.8× 7.3k 0.8× 5.0k 0.9× 6.4k 1.4× 4.8k 1.1× 378 21.4k
Stephan R. Targan United States 90 18.3k 1.5× 12.5k 1.4× 6.0k 1.1× 11.5k 2.4× 4.4k 1.0× 434 31.0k
David T. Rubin United States 64 11.1k 0.9× 8.5k 1.0× 5.1k 1.0× 2.3k 0.5× 2.6k 0.6× 727 18.1k
Sander J. H. van Deventer Netherlands 72 7.7k 0.6× 7.7k 0.9× 4.9k 0.9× 7.3k 1.5× 4.0k 0.9× 269 22.1k
Axel Dignaß Germany 55 10.1k 0.8× 7.1k 0.8× 5.1k 1.0× 2.7k 0.6× 2.3k 0.5× 282 17.3k
Ole Haagen Nielsen Denmark 62 5.9k 0.5× 3.7k 0.4× 3.5k 0.7× 3.6k 0.8× 3.5k 0.8× 342 14.5k
Simon Travis United Kingdom 67 14.9k 1.2× 11.7k 1.3× 7.5k 1.4× 3.8k 0.8× 1.6k 0.4× 433 21.8k
Walter Reinisch Austria 57 14.1k 1.1× 11.0k 1.2× 5.3k 1.0× 4.0k 0.9× 2.1k 0.5× 340 19.9k

Countries citing papers authored by Marc Ferrante

Since Specialization
Citations

This map shows the geographic impact of Marc Ferrante's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Ferrante with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Ferrante more than expected).

Fields of papers citing papers by Marc Ferrante

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Ferrante. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Ferrante. The network helps show where Marc Ferrante may publish in the future.

Co-authorship network of co-authors of Marc Ferrante

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Ferrante. A scholar is included among the top collaborators of Marc Ferrante based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Ferrante. Marc Ferrante is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jairath, Vipul, Geert D’Haens, Bruce E. Sands, et al.. (2025). Bowel Urgency in Crohn’s Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Study. Clinical Gastroenterology and Hepatology. 24(2). 463–473.e5.
2.
Peyrin‐Biroulet, Laurent, Perttu Arkkila, Alessandro Armuzzi, et al.. (2024). Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials. BMC Gastroenterology. 24(1). 121–121. 3 indexed citations
3.
Jairath, Vipul, Brian G. Feagan, Mark S. Silverberg, et al.. (2024). Mucosal Healing With Vedolizumab in Patients With Chronic Pouchitis: EARNEST, a Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Gastroenterology and Hepatology. 23(2). 321–330.e3. 1 indexed citations
4.
Bislenghi, Gabriele, W. De Coster, Albert Wolthuis, et al.. (2024). Ileal pouch-anal anastomosis for ulcerative colitis: 30-year analysis on surgical evolution and patient outcome. BJS Open. 9(1).
5.
Ferrante, Marc, Silvio Danese, M Chen, et al.. (2024). OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study. Journal of Crohn s and Colitis. 18(Supplement_1). i7–i9. 11 indexed citations
6.
Long, Millie D., Javier P. Gisbert, Kim McGinnis, et al.. (2023). IMPROVEMENT IN BOWEL URGENCY IS ASSOCIATED WITH STOOL FREQUENCY AND RECTAL BLEEDING REMISSION AT 12 AND 52 WEEKS IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS. Inflammatory Bowel Diseases. 29(Supplement_1). S10–S11. 1 indexed citations
7.
Travis, Simon, Mark S. Silverberg, Silvio Danese, et al.. (2023). Vedolizumab for the Treatment of Chronic Pouchitis. New England Journal of Medicine. 388(13). 1191–1200. 58 indexed citations
8.
9.
Panés, Julián, Gerd Bouma, Marc Ferrante, et al.. (2022). INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn’s Disease Treated in the ADMIRE-CD Trial. Inflammatory Bowel Diseases. 28(11). 1737–1745. 35 indexed citations
10.
Sudhakar, Padhmanand, Judith Wellens, Bram Verstockt, et al.. (2022). Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches?. Gut. 72(1). 192–204. 16 indexed citations
11.
Walentynowicz, Marta, Sofie Coenen, Johan W.S. Vlaeyen, et al.. (2020). Worries and concerns of inflammatory bowel disease (IBD) patients in Belgium – a validation of the Dutch rating form. Scandinavian Journal of Gastroenterology. 55(12). 1427–1432. 5 indexed citations
12.
Bossuyt, Peter, Hiroshi Nakase, Séverine Vermeire, et al.. (2020). Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density. Gut. 69(10). 1778–1786. 95 indexed citations
13.
Verstockt, Bram, Sare Verstockt, Kaline Arnauts, et al.. (2020). Intestinal Receptor of SARS-CoV-2 in Inflamed IBD Tissue Seems Downregulated by HNF4A in Ileum and Upregulated by Interferon Regulating Factors in Colon. Journal of Crohn s and Colitis. 15(3). 485–498. 30 indexed citations
14.
Verstockt, Bram, Erwin Dreesen, Maja Noman, et al.. (2019). Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates. Journal of Crohn s and Colitis. 13(7). 864–872. 80 indexed citations
15.
Papamichael, Konstantinos, Thomas Billiet, Niels Vande Casteele, et al.. (2016). Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab. Journal of Crohn s and Colitis. 10(9). 1015–1023. 61 indexed citations
16.
Billiet, Thomas, Isabelle Cleynen, Marc Ferrante, et al.. (2016). A variable number of tandem repeat polymorphism in the promotor region of the neonatal Fc receptor affects anti-tumour necrosis factor serum levels in inflammatory bowel disease. 10. 2 indexed citations
17.
Cleynen, Isabelle, Wouter Van Moerkercke, Thomas Billiet, et al.. (2015). Anti-TNF-induced skin manifestations in IBD patients: role for increased drug exposure?. 9. 1 indexed citations
18.
Jauregui-Amezaga, Aranzazu, Gert De Hertogh, Talat Bessissow, et al.. (2015). A Simplified Histological Geboes Score for Ulcerative Colitis. Gastroenterology. 148(4). 1 indexed citations
19.
Bessissow, Talat, Bart Lemmens, Marc Ferrante, et al.. (2012). Prognostic Value of Serologic and Histologic Markers on Clinical Relapse in Ulcerative Colitis Patients With Mucosal Healing. The American Journal of Gastroenterology. 107(11). 1684–1692. 215 indexed citations
20.
Hlavatý, Tibor, Philippe Persoons, Séverine Vermeire, et al.. (2005). IBDQ score is a sensitive instrument to assess short-term changes in disease related quality of life in patients with luminal Crohn's disease. Gastroenterology. 128(4).

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julián Panés Breakdown of academic impact, for papers by Toshifumi Hibi∥ Breakdown of academic impact, for papers by María T. Abreu Breakdown of academic impact, for papers by Stephan R. Targan Breakdown of academic impact, for papers by David T. Rubin Breakdown of academic impact, for papers by Sander J. H. van Deventer Breakdown of academic impact, for papers by Axel Dignaß Breakdown of academic impact, for papers by Ole Haagen Nielsen Breakdown of academic impact, for papers by Simon Travis Breakdown of academic impact, for papers by Walter Reinisch
Rankless by CCL
2026